RQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Advancing next-generation therapeutics for migraine and other headache disorders
Develops treatments for chronic lung diseases, focusing on viral respiratory infections
Develops preventive RNAi medicines for cardiovascular disease prediction and prevention
Pitching Forbion? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room